Arcturus Therapeutics (NASDAQ:ARCT) Downgraded by StockNews.com to Sell

Arcturus Therapeutics (NASDAQ:ARCTGet Rating) was downgraded by research analysts at StockNews.com from a “hold” rating to a “sell” rating in a research report issued on Thursday.

A number of other research analysts have also weighed in on the company. Brookline Capital Management reissued a “buy” rating on shares of Arcturus Therapeutics in a report on Wednesday, August 10th. Raymond James cut Arcturus Therapeutics from a “market perform” rating to an “underperform” rating in a report on Wednesday, August 10th. Barclays reduced their price target on shares of Arcturus Therapeutics from $17.00 to $16.00 and set an “underweight” rating on the stock in a research report on Wednesday, August 10th. The Goldman Sachs Group lowered their target price on shares of Arcturus Therapeutics from $14.00 to $8.00 and set a “sell” rating for the company in a research note on Tuesday, May 24th. Finally, Wells Fargo & Company lowered their target price on Arcturus Therapeutics from $105.00 to $98.00 and set an “overweight” rating for the company in a report on Wednesday, August 10th. Four equities research analysts have rated the stock with a sell rating, two have assigned a hold rating and three have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $38.75.

Arcturus Therapeutics Price Performance

Arcturus Therapeutics stock opened at $15.87 on Thursday. The company has a market cap of $421.76 million, a price-to-earnings ratio of -2.53 and a beta of 2.74. Arcturus Therapeutics has a 52-week low of $11.70 and a 52-week high of $55.46. The company has a quick ratio of 3.14, a current ratio of 3.14 and a debt-to-equity ratio of 0.21. The firm’s fifty day moving average is $17.19 and its 200 day moving average is $19.34.

Arcturus Therapeutics (NASDAQ:ARCTGet Rating) last released its earnings results on Tuesday, August 9th. The biotechnology company reported ($0.82) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.90) by $1.08. The business had revenue of $27.09 million for the quarter, compared to analyst estimates of $3.33 million. Arcturus Therapeutics had a negative return on equity of 78.54% and a negative net margin of 407.91%. During the same quarter last year, the firm posted ($2.07) earnings per share. Sell-side analysts forecast that Arcturus Therapeutics will post -6.5 EPS for the current fiscal year.

Hedge Funds Weigh In On Arcturus Therapeutics

Large investors have recently added to or reduced their stakes in the business. Daiwa Securities Group Inc. raised its position in shares of Arcturus Therapeutics by 44.0% in the 1st quarter. Daiwa Securities Group Inc. now owns 3,503 shares of the biotechnology company’s stock worth $94,000 after buying an additional 1,071 shares during the period. Byrne Asset Management LLC grew its holdings in shares of Arcturus Therapeutics by 29.4% during the 1st quarter. Byrne Asset Management LLC now owns 4,000 shares of the biotechnology company’s stock worth $108,000 after purchasing an additional 910 shares during the period. KRS Capital Management LLC acquired a new stake in Arcturus Therapeutics during the 4th quarter worth approximately $51,000. Los Angeles Capital Management LLC purchased a new position in Arcturus Therapeutics in the first quarter valued at approximately $1,608,000. Finally, Formidable Asset Management LLC lifted its position in Arcturus Therapeutics by 8.5% during the first quarter. Formidable Asset Management LLC now owns 14,050 shares of the biotechnology company’s stock valued at $379,000 after buying an additional 1,100 shares in the last quarter. 83.55% of the stock is currently owned by hedge funds and other institutional investors.

Arcturus Therapeutics Company Profile

(Get Rating)

Arcturus Therapeutics Holdings Inc, an RNA medicines company, focuses on the development of vaccines for infectious, and liver and respiratory rare diseases in the United States. The company's development programs comprise LUNAR-OTC development program for ornithine transcarbamylase (OTC) deficiency; and LUNAR-CF program for cystic fibrosis lung disease caused by mutations in cystic fibrosis transmembrane conductance regulator (CFTR) gene, as well as vaccine programs include LUNAR-COV19 and LUNAR-FLU.

Recommended Stories

Analyst Recommendations for Arcturus Therapeutics (NASDAQ:ARCT)

Receive News & Ratings for Arcturus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arcturus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.